CJC-1295 vs PT-141
Head-to-head comparison of CJC-1295 (Growth Hormone Releasing Hormone Analog) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
| Property | CJC-1295 | PT-141 |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Growth Hormone Releasing Hormone Analog | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 3,367.97 Da | 1,025.2 Da |
| Half-Life | ~6-8 days (DAC) | ~2.7 hours |
| Amino Acids | 30 | 7 |
| Typical Dose | 1-2 mg/week | 1.75 mg |
| Route | SC | SC |
| Purity | — | — |
| Studies Count | 167 | 178 |
| Research Status | Clinical Trials | FDA Approved |
CJC-1295 Benefits
- ✓Sustained GH release over days
- ✓Improved body composition
- ✓Enhanced deep sleep quality
- ✓Accelerated recovery from training
- ✓Increased protein synthesis
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
CJC-1295 Dosing
Without DAC: 100-200 mcg SC 2-3 times daily|With DAC: 1-2 mg SC once or twice weekly|Combined with Ipamorelin: 100 mcg each, 2-3x daily
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
CJC-1295 Side Effects
- ⚠Common (Mild): Water retention, tingling/numbness, flushing
- ⚠Moderate: Joint stiffness, carpal tunnel-like symptoms
- ⚠Rare: Elevated blood sugar (transient)
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
CJC-1295
CJC-1295 has good pre-clinical and early clinical data. The DAC variant shows sustained GH elevation for days. Often combined with GHRPs for synergistic GH release.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.